Trial Profile

Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3372689

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 3372689 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

30 Jul 2021 Results reporting safety and pharmacokinetics of LY3372689 after single and multiple oral doses in healthy volunteers from two clinical studies: NCT03819270 (SAD study) and NCT04106206 (MAD study) presented at the Alzheimer's Association International Conference 2021
21 Jul 2020 According to an Eli Lilly and Company media release, data from this trial will be presented at the upcoming Alzheimers Association International Conference 2020 (AAIC 2020) which will be held virtually July 27-31, 2020
22 Apr 2020 Status changed from suspended to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com